



CollPlant
Biotechnologies

Pioneering
Regenerative
Medicine

CollPlant Biotechnologies Ltd.
4 Oppenheimer Street, Weizmann Science Park
Rehovot 7670104 Israel
Phone: +972 (73) 2325600
www.collplant.com

Company Overview

CollPlant Biotechnologies (NASDAQ:CLGN) is a regenerative and aesthetic medicine company focused on tissue regeneration and 3D bioprinting of tissues and organs. The Company's proprietary technology platform enables mass production of recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants. rhCollagen-based products including CollPlant's BioInks are used in 3D bioprinting of tissues and organs, as well as in medical aesthetics. CollPlant recently signed an agreement worth up to \$103 million, plus royalties, for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the \$6.2 billion dermal filler market. CollPlant is developing 3D bioprinted breast implants for regeneration of breast tissue and is actively pursuing additional business development collaborations with top-tier companies for use of its BioInks in the production of unlimited and economical manufactured organs.

EQUITY OVERVIEW (as of 05/28/2021)

NASDAQ: CLGN

Stock Price: ~ \$ 16.22

Trading Volume (3 months avg.): 49,000

Market Cap: ~ \$165 M

Shares Outstanding: ~ 10.2 M

Revenues (TTM): \$20 M

STRATEGIC AGREEMENTS WITH:


Allergan Aesthetics/AbbVie (NYSE:ABBV)

3D Systems (NYSE:DDD)

3D BIOPRINTING



MEDICAL AESTHETICS



Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of CollPlant Biotechnologies Ltd.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Investment Highlights

The Only Commercially Viable Production of True Human Collagen

CollPlant has the only commercially viable technology currently available to mass-produce true Type I recombinant human collagen (rhCollagen). Collagen is an essential building block of the human body, providing structural support and biological signals to connective tissues and organs, and therefore it is a crucial component for tissue regeneration. CollPlant's proprietary technology includes the introduction into tobacco plants of 5 human genes that are essential for the synthesis of Type I collagen. These transgenic tobacco plants produce human collagen that is superior to collagen currently on the market sourced from animals and human cadavers. rhCollagen is identical to natural human collagen, therefore it does not elicit an adverse immune response in humans. Its plant origin yields a safe product with more consistent properties, making it the ideal building block for regenerative medicine. CollPlant's rhCollagen is a broadly applicable technology platform that is cost effective and enables products for medical uses with superior properties.

Developing Regenerative Dermal Fillers with Allergan in \$6.2 B Market

CollPlant has entered into a development and commercialization agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), for CollPlant's rhCollagen to be used in dermal and soft tissue filler products. Allergan is a global leader in the \$6.2 billion dermal filler market estimated to grow to \$10 billion by 2026. In an agreement worth up to \$103 million, CollPlant has received \$14 million upfront and is entitled to an additional \$89 million in milestone payments, royalty payments, and a fee for the manufacture and supply of rhCollagen to Allergan Aesthetics. Combining rhCollagen's superior properties with Allergan's propriety technologies, this collaboration is expected to create a paradigm shift in the medical aesthetic field by providing next-generation regenerative products with long lasting results. CollPlant is also developing a photocurable dermal filler, to which AbbVie has a right of first negotiation for a worldwide exclusive license. This photocurable filler is intended to provide several revolutionary advantages including: lifting, sculpturing ability, and longevity through retention to the host tissue, and tissue regeneration.

BioInks for 3D Organ Bioprinting with Top-Tier Collaborators

rhCollagen-based BioInks are ideal for 3D bioprinting of organs, tissues, endocrine glands, and scaffolds, enabling unlimited and economical access to manufactured organs around the world and the potential to save millions of lives annually. CollPlant has partnered with 3D Systems (NYSE:DDD) a leader in 3D printing, to provide 3D bioprinting solutions that combine 3D Systems' printers with CollPlant's BioInks. Additionally, CollPlant's industry collaborators include the Advanced Regenerative Manufacturing Institute (ARMI) and RegenMed Development Organization (ReMDO).

3D Bioprinted Regenerative Breast Implants for \$1.4 B Market

CollPlant is developing 3D bioprinted breast implants aimed at providing a revolutionary alternative to current implants which are associated with high risk of adverse events. These regenerative implants are designed to gradually degrade and be replaced by newly grown natural breast tissue. This program is currently in the pre-clinical phase, and Allergan has the right of first negotiation for the indication.